Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,730 shares of the biopharmaceutical company's stock after selling 11,502 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Bristol Myers Squibb were worth $1,752,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in BMY. King Wealth Management Group grew its position in shares of Bristol Myers Squibb by 2.6% in the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after buying an additional 182 shares during the period. Thoroughbred Financial Services LLC grew its position in shares of Bristol Myers Squibb by 1.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 190 shares during the period. Marcum Wealth LLC boosted its stake in Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after purchasing an additional 193 shares in the last quarter. Leelyn Smith LLC boosted its stake in Bristol Myers Squibb by 0.5% in the 4th quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company's stock worth $2,698,000 after purchasing an additional 215 shares in the last quarter. Finally, Heron Bay Capital Management boosted its stake in Bristol Myers Squibb by 2.1% in the 4th quarter. Heron Bay Capital Management now owns 10,795 shares of the biopharmaceutical company's stock worth $611,000 after purchasing an additional 220 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.07% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. UBS Group dropped their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $58.00.

Bristol Myers Squibb Stock Up 1.2%

NYSE BMY opened at $47.07 on Wednesday. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company has a market capitalization of $95.79 billion, a P/E ratio of 17.63, a P/E/G ratio of 1.38 and a beta of 0.36. Bristol Myers Squibb Company has a one year low of $39.71 and a one year high of $63.33. The stock has a 50 day moving average price of $47.65 and a 200-day moving average price of $53.46.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($4.40) EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.27%. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.